老虎证券
Invest
Pricing
Rewards
Support
Learn
About
Quotes
TigerAI
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Ophthotech Corporation
1.39
0.0000
成交量：
- -
成交额：
- -
市值：
5,757.60万
市盈率：
0.82
高：
1.39
开：
1.39
低：
1.39
收：
1.39
52周最高：
4.50
52周最低：
1.02
股本：
4,142.15万
流通股本：
2,660.83万
量比：
- -
换手率：
- -
股息：
- -
股息率：
- -
每股收益(TTM):
1.70
每股收益(LYR):
1.70
净资产收益率：
--
总资产收益率：
--
市净率：
0.46
市盈率(LYR):
0.82
数据加载中...
总览
公司
新闻资讯
公告
公司资料
公司名字：
Ophthotech Corporation
交易所：
NASDAQ
成立时间：
- -
员工人数：
- -
公司地址：
- -
官网：
http://www.ophthotech.com
邮编：
- -
电话：
- -
传真：
- -
简介：
Ophthotech Corporation成立于2007年1月5日，在美国特拉华州。 公司是一家生物制药公司，专门从事新型疗法的发展，治疗眼睛的背部疾病，重点开发治疗年龄相关性黄斑变性，或AMD。 公司的最先进产品的候选是Fovista，这是在第3阶段的临床开发组合使用与代表保健为湿性AMD的治疗的目前标准的抗VEGF药物。公司已完成了第一阶段1和一个2b期Fovista的组合给予的抗VEGF药物Lucentis的临床试验。公司也正在开发其候选产品Zimura，对于患者的地理萎缩，干性AMD的一种形式的治疗，结合抗VEGF疗法用于治疗息肉状脉络膜血管病变，湿性AMD的特定类型，患者谁不与抗-VEGF单一疗法充分应对处理或为其抗-VEGF单一疗法失败，并且，潜在地，在用抗VEGF治疗和Fovista对于抗VEGF抗性湿性AMD的患者的治疗中谁被认为具有补体结合介导的炎症。
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/OPHT/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"OPHT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPHT\",,,,,undefined,":{"symbol":"OPHT","market":"US","secType":"STK","nameCN":"Ophthotech Corporation","latestPrice":1.39,"timestamp":1567195200000,"preClose":1.39,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":26608262,"shares":41421548,"eps":1.7,"marketStatus":"未开盘","change":0,"latestTime":"08-30 16:00:00 EDT","open":1.39,"high":1.39,"low":1.39,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.7,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.39,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OPHT\",,,,,undefined,":{"symbol":"OPHT","floatShares":26608262,"roa":"--","roe":"--","lyrEps":1.702247,"shares":41421548,"dividePrice":0,"high":1.39,"amplitude":0,"preClose":1.39,"low":1.39,"week52Low":1.02,"pbRate":"0.46","week52High":4.5,"institutionHeld":0,"latestPrice":1.39,"eps":1.7,"divideRate":0,"volume":0,"delay":0,"ttmEps":1.7,"open":1.39,"prevYearClose":1.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OPHT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-02-26","symbol":"OPHT","fiscalQuarterEnding":"2018/12","expectedEps":-0.36,"name":null,"time":"盘前","type":"earning","dateTimestamp":1551157200000,"reportTimeType":"pre","actualEps":-0.53},{"market":"US","date":"2018-10-31","symbol":"OPHT","fiscalQuarterEnding":"2018/09","expectedEps":-0.43,"name":null,"time":"盘前","type":"earning","dateTimestamp":1540958400000,"reportTimeType":"pre","actualEps":-0.41},{"market":"US","date":"2018-08-01","symbol":"OPHT","fiscalQuarterEnding":"2018/06","expectedEps":-0.4,"name":null,"time":"盘前","type":"earning","dateTimestamp":1533096000000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2018-05-09","symbol":"OPHT","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"盘前","type":"earning","dateTimestamp":1525838400000,"reportTimeType":"pre","actualEps":-0.36},{"market":"US","date":"2018-02-27","symbol":"OPHT","fiscalQuarterEnding":"2017/12","expectedEps":-0.58,"name":null,"time":"盘前","type":"earning","dateTimestamp":1519707600000,"reportTimeType":"pre","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OPHT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OPHT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.ophthotech.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ophthotech Corporation成立于2007年1月5日，在美国特拉华州。 公司是一家生物制药公司，专门从事新型疗法的发展，治疗眼睛的背部疾病，重点开发治疗年龄相关性黄斑变性，或AMD。 公司的最先进产品的候选是Fovista，这是在第3阶段的临床开发组合使用与代表保健为湿性AMD的治疗的目前标准的抗VEGF药物。公司已完成了第一阶段1和一个2b期Fovista的组合给予的抗VEGF药物Lucentis的临床试验。公司也正在开发其候选产品Zimura，对于患者的地理萎缩，干性AMD的一种形式的治疗，结合抗VEGF疗法用于治疗息肉状脉络膜血管病变，湿性AMD的特定类型，患者谁不与抗-VEGF单一疗法充分应对处理或为其抗-VEGF单一疗法失败，并且，潜在地，在用抗VEGF治疗和Fovista对于抗VEGF抗性湿性AMD的患者的治疗中谁被认为具有补体结合介导的炎症。","exchange":"NASDAQ","name":"Ophthotech Corporation","nameEN":"Ophthotech"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OPHT\",market:\"US\",,,undefined,":null}}